Drug Database · Clinicians

Human normal immunoglobulin

Brands (15) Gamma I.V., Privigen, Bioven Mono…Show all

Immunoglobulin; Immune sera and immunoglobulin PH FDA category

Rx · Prescription drug18 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: EU Summary of Product Characteristics (EMA), Kiovig, revised June 27, 2022, reproduced with acknowledgment of the source (EPAR page · product information (PDF)). Marketing authorization holder: Takeda Manufacturing Austria AG. Text is quoted verbatim, in the original British spelling. This generic has no US FDA label. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

SmPC 4.1 Therapeutic indications EU SmPC (EMA)

Replacement therapy in adults, and children and adolescents (0-18 years) in:

      Primary immunodeficiency syndromes (PID) with impaired antibody production (see
       section 4.4).
      Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections,
       ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or
       serum IgG level of <4 g/l.

*PSAF = failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide
and polypeptide antigen vaccines

Immunomodulation in adults, and children and adolescents (0-18 years) in:

     Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery
      to correct the platelet count.
     Guillain Barré syndrome.
     Kawasaki disease (in conjunction with acetylsalicylic acid; see 4.2).
     Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
     Multifocal Motor Neuropathy (MMN).

Contraindications

SmPC 4.3 Contraindications EU SmPC (EMA)

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Hypersensitivity to human immunoglobulins, especially in patients with antibodies against IgA.

Patients with selective IgA deficiency who developed antibodies to IgA, as administering an IgA containing product can result in anaphylaxis.

Dosing: Adult

SmPC 4.2 Posology and method of administration EU SmPC (EMA)

Replacement therapy should be initiated and monitored under the supervision of a physician experienced in the treatment of immunodeficiency.

Posology

The dose and dose regimen is dependent on the indication.

In replacement therapy the dose may need to be individualised for each patient dependent on the pharmacokinetic and clinical response. Dose based on bodyweight may require adjustment in underweight or overweight patients.

The following dose regimens are given as a guideline.

Replacement therapy in primary immunodeficiency syndromes

The dose regimen should achieve a trough level of IgG (measured before the next infusion) of at least 5 to 6 g/L. Three to six months are required after the initiation of therapy for equilibration (steady-state IgG levels) to occur. The recommended starting dose is 0.4-0.8 g/kg given once, followed by at least 0.2 g/kg given every three to four weeks.

The dose required to achieve a trough level of 5-6 g/L is of the order of 0.2-0.8 g/kg/month. The dose interval when steady state has been reached varies from 3-4 weeks.

IgG trough levels should be measured and assessed in conjunction with the incidence of infection. To reduce the rate of bacterial infection, it may be necessary to increase the dose and aim for higher trough levels.

Secondary immunodeficiencies (as defined in 4.1.)

The recommended dose is 0.2-0.4 g/kg every three to four weeks.

IgG trough levels should be measured and assessed in conjunction with the incidence of infection. Dose should be adjusted as necessary to achieve optimal protection against infections, an increase may be necessary in patients with persisting infection; a dose decrease can be considered when the patient remains infection free.

Primary immune thrombocytopenia

There are two alternative treatment schedules:
     0.8-1g/kg given on day one; this dose may be repeated once within 3 days
     0.4 g/kg given daily for two to five days.

The treatment can be repeated if relapse occurs.

Guillain Barré syndrome

0.4 g/kg/day over 5 days (possible repeat of dosing in case of relapse).

Kawasaki Disease

2 g/kg should be administered as a single dose. Patients should receive concomitant treatment with acetylsalicylic acid.

Chronic inflammatory demyelinating polyneuropathy (CIDP)

Starting dose: 2 g/kg divided over 2 -5 consecutive days

Maintenance doses: 1 g/kg over 1-2 consecutive days every 3 weeks. The treatment effect should be evaluated after each cycle; if no treatment effect is seen after 6 months, the treatment should be discontinued. If the treatment is effective long term treatment should be subject to the physicians discretion based upon the patient response and maintenance response. The dosing and intervals may have to be adapted according to the individual course of the disease.

Multifocal Motor Neuropathy (MMN)

Starting dose: 2 g/kg given over 2-5 consecutive days.

Maintenance dose: 1 g/kg every 2 to 4 weeks or 2 g/kg every 4 to 8 weeks over 2-5 days. The treatment effect should be evaluated after each cycle; if no treatment effect is seen after 6 months, the treatment should be discontinued. If the treatment is effective long term treatment should be subject to the physicians discretion based upon the patient response and maintenance response. The dosing and intervals may have to be adapted according to the individual course of the disease.

The dose recommendations are summarised in the following table:

              Indication                              Dose                 Frequency of injections
Replacement therapy in primary                   starting dose:
immunodeficiency                                  0.4-0.8 g/kg

                                              maintenance dose: every 3-4 weeks to obtain IgG
                                                0.2-0.8 g/kg    trough level of at least 5-6 g/l
Replacement therapy in secondary                0.2-0.4 g/kg    every 3-4 weeks to obtain IgG
immunodeficiency                                                trough level of at least 5-6 g/l

Immunomodulation:

Primary immune thrombocytopenia                   0.8-1 g/kg        on day 1, possibly repeated once
                                                                    within 3 days
                                                      or
                                                  0.4 g/kg/d        for 2-5 days

Guillain Barré syndrome                           0.4 g/kg/d        for 5 days

Kawasaki disease                                    2 g/kg          in one dose in association with
                                                                    acetylsalicylic acid

Chronic inflammatory demyelinating               starting dose      In divided doses over 2-5 days
polyradiculoneuropathy (CIDP)                        2g/kg

                                              maintenance dose: every 3 weeks over 1-2 days
                                                    1g/kg

Multifocal Motor Neuropathy (MMN)                  starting         given over 2-5 days
                                                 dose: 2 g/kg

                                                 maintenance        every 2-4 weeks
                                                 dose: 1 g/kg

                                                      or            or
                                                    2 g/kg          every 4-8 weeks over 2-5 days

Paediatric population

The posology in children and adolescents (0-18 years) is not different to that of adults as the posology for each indication is given by body weight and adjusted to the clinical outcome of the above mentioned conditions.

Hepatic impairment

No evidence is available to require a dose adjustment.

Renal impairment

No dose adjustment unless clinically warranted, see section 4.4.

Elderly

No dose adjustment unless clinically warranted, see section 4.4.

Method of administration

For intravenous use. Human normal immunoglobulin should be infused intravenously at an initial rate of 0.5 ml/kg BW/hr for 30 minutes. If well tolerated (see section 4.4), the rate of administration may gradually be increased to a maximum of 6 ml/kg BW/hr. Clinical data obtained from a limited number of patients also indicate that adult PID patients may tolerate an infusion rate of up to 8 ml/kg BW/hr. For further precautions for use see section 4.4.

If dilution prior to infusion is required, KIOVIG may be diluted with 5% glucose solution to a final concentration of 50 mg/ml (5% immunoglobulin). For instructions on dilution of the medicinal product before administration, see section 6.6.

Any infusion-related adverse events should be treated by lowering infusion rates or by stopping the infusion.

Dosing: Altered kidney function

SmPC 4.2 Posology and method of administration · Renal impairment

No dose adjustment unless clinically warranted, see section 4.4.

Source: EU Summary of Product Characteristics (EMA), Kiovig, revised June 27, 2022, reproduced with acknowledgment of the source (verbatim). This generic has no US FDA label.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

Hepatic impairment (SmPC 4.2) EU SmPC (EMA)

Hepatic impairment

No evidence is available to require a dose adjustment.

Dosing: Pediatric

Pediatric population (SmPC 4.2) EU SmPC (EMA)

Paediatric population

The posology in children and adolescents (0-18 years) is not different to that of adults as the posology for each indication is given by body weight and adjusted to the clinical outcome of the above mentioned conditions.

Dosing: Older adult

Older adults (SmPC 4.2) EU SmPC (EMA)

Elderly

No dose adjustment unless clinically warranted, see section 4.4.

Dosage forms

Philippines

  • ) solution for infusion: 50 mg/mL, 100 mg/mL, 5,000 mg/100 mL (50 mg/mL
  • Solution for infusion: 50 mg/mL, 100 mg/mL
  • ) solution for injection: 50 mg/mL (2,500 mg/50 mL, 50 mg/mL (2.5 g/50 mL, 50 mg/mL (5 g/100 mL
  • Solution for injection: 50 mg/mL

Registered products in the Philippines

18 products registered with the Food and Drug Administration (FDA) Philippines list Human normal immunoglobulin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products18
Philippine FDA-registered products for Human normal immunoglobulin
Package insert
Bioven MonoHuman Normal Immunoglobulin
50 mg/mL (5% w/v) Solution for Injection (I.V.)Type I glass vial with bromobutyl rubber stopper sealed with aluminum cap x 50 mL and 100 mL (Box of 1's)
Rx
Biofarma Plasma Limited Liability CompanyUkraine
Importer: Ambicare Pharmaceuticals Inc.
BRP-086
May 29, 2029
Gamma I.V.Human Normal Immunoglobulin (IGIV)
50 mg/mL (2.5 g/50 mL) Solution for Injection (IV)50 mL USP Type 1 Glass Vial (Box of 1's)
Rx
Bharat Serums and Vaccines LimitedIndia
BSV Bioscience Phils. Inc.
BR-671
Feb 10, 2031
Gamma I.V.Human Normal Immunoglobulin (IGIV)
50 mg/mL (5 g/100 mL) Solution for Injection (IV)100 mL USP Type 1 Colorless Flint Glass Vial with Rubber Bung and White Aluminum Flip Off Seal (Box of 1's)
Rx
Bharat Serums and Vaccines LimitedIndia
BSV Bioscience Phils. Inc.
BR-636
Jun 16, 2031
Gamma-I.V.Human Normal Immunoglobulin
5% (50 mg/mL) Solution for Infusion (IV)Glass Vial x 50 mL and 100 mL (Box of 1's)
Rx
Reliance Life Sciences Pvt. Ltd.India
BSV Bioscience Phils. Inc.Importer: Ambica International Corporation
BRP-052-04
Mar 7, 2029
Gamunex-CHuman Normal Immunoglobulin (IVIg)
10% (100 mg/mL) Solution for Infusion (IV/SC)Clear, colorless Type I glass vial x 10 mL, 25 mL, 50 mL and 100 mL (Box of 1's)
Rx
Grifols Therapeutics LLCU.S.A
GB Distributors Inc.
BR-733
May 26, 2027
HumoglobHuman Normal Immunoglobulin (IGIV)
50 mg/mL Solution for Injection (IV Infusion)Glass Vial in a box (50mL and 100mL)
Rx
SK Plasma Co., Ltd.Republic of Korea
International Apex Pharmaceuticals, Inc.
BR-874
Sep 11, 2027
I.V. - Globulin SN InjectionHuman Normal Immunoglobulin
50 mg/mL (2,500 mg/ 50mL) Solution for Injection (IV)50 mL vial (Box of 1's)
Rx
GC Biopharma Corp.Republic of Korea
Vizcarra Pharmaceutical, Inc.
BR-469
Sep 6, 2030
Ig VenaHuman Normal Immunoglobulin
50 mg/mL Solution for Infusion (IV)Clear glass vial x 20 mL, 50 mL, 100 mL and 200 mL (Box of 1's)
Rx
Kedrion S.p.A.Italy
Metro Drug, Inc.Importer: New Marketlink Pharmaceutical Corporation
BR-651
Nov 7, 2028
ImmubulinHuman Normal Immunoglobulin
5% (50 mg/mL) Solution for Infusion (IV)Glass vial x 50 mL and 100 mL (Box of 1's)
Rx
Reliance Life Sciences Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
BRP-052-02
Mar 7, 2029
ImmunorelHuman Normal Immunoglobulin
5% (50 mg/mL) Solution for Infusion (IV)Glass Vial x 10 mL, 20 mL, 50 mL, 100 ml, and 200 mL (Box of 1's)
Rx
Reliance Life Sciences Pvt. Ltd.India
Ambica International Corporation
BRP-052
Mar 7, 2029
IV-Globulin SN InjectionHuman Normal Immunoglobulin
5,000 mg/100 mL (50 mg/mL) Solution for Infusion (IV)Glass vial x 100 mL (Box of 1's)
Rx
Green Cross Corp.Korea
Vizcarra Pharmaceutical Incorporated
BR-897
Apr 4, 2028
NormglubinHuman Normal Immunoglobulin
5% (50 mg/mL) Solution for Infusion (IV)Glass vial x 50 mL and 100 mL (Box of 1's)
Rx
Reliance Life Sciences Pvt. Ltd.India
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
BRP-052-03
Mar 7, 2029
Octagam 10%Human Normal Immunoglobulin
100mg/mL (10% w/v) Solution for Infusion (IV)Type II Glass Bottle with Bromobutyl Rubber Stopper sealed with Aluminum Flip-off Cap (20 mL solution in 30 mL; 50 mL Solution in 70 mL; 100 mL; 200 mL Solution in 250 mL) (Box of 1’s)
Rx
Octapharma Pharmazeutika Produktionsges.m.b.HAustria
Medlink Marketing Inc.Importer: Zenith Bloom Company Inc.
BR-1155
Jun 7, 2031
Octagam 5%Human Normal Immunoglobulin
50 mg/mL (5% w/v) Solution for Infusion (IV)Type II Glass Bottle with Bromobutyl Rubber Stopper sealed with Aluminum flip-off cap (20 mL Solution in 30 mL; 50 mL solution in 70 mL; 100 mL; 200 mL Solution in 250 mL) (Box of 1’s)
Rx
Octapharma Pharmazeutika Produktionsges.m.b.HAustria
Medlink Marketing Inc.Importer: Zenith Bloom Company Inc.
BR-1156
Jun 7, 2031
PentaglobinHuman Normal Immunoglobulin
50 mg/mL Solution for Infusion (IV)EP Type II glass vial with light grey bromobutyl rubber stopper sealed with colorless aluminum pulloff cap with center tear off [Net content: 50 mL & 100 mL] (Box of 1's)
Rx
Biotest AGGermany
EC Zuric Biotherapies, Inc.
BR-1380
Nov 16, 2031
PrivigenHuman Normal Immunoglobulin
100 mg/mL (10% w/v) Solution for Infusion (IV)Type II glass vial x 50 mL, 100 mL and 200 mL (Box of 1's)
Rx
CSL Behring AGSwitzerland
Zuellig Pharma Corporation
BR-1243
Oct 5, 2027
PrivigenHuman Normal Immunoglobulin
100 mg/mL (10% w/v) Solution for Infusion (IV)Type I glass vial x 25 mL (Box of 1's)
Rx
CSL Behring AGSwitzerland
Zuellig Pharma Corporation
BR-1244
Oct 5, 2027
ProivigHuman Normal Immunoglobulin
5% (50 mg/mL) Solution For Infusion (Iv)Glass vial x 10 mL, 20 mL, 50 mL, 100 mL and 200 mL (Box of 1's)
Rx
Reliance Life Sciences Pvt. Lt.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
BRP-052-01
Mar 7, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

SmPC 4.4 Special warnings and precautions for use EU SmPC (EMA)

Infusion reaction

Certain severe adverse reactions (e.g. headache, flushing, chills, myalgia, wheezing, tachycardia, lower back pain, nausea, and hypotension) may be related to the rate of infusion. The recommended infusion rate given under section 4.2 must be closely followed. Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period. Certain adverse reactions may occur more frequently  in case of high rate of infusion  in patients who receive human normal immunoglobulin for the first time or, in rare cases, when the human normal immunoglobulin product is switched or when there has been a long interval since the previous infusion.  in patients with an untreated infection or underlying chronic inflammation.

Precautions for use

Potential complications can often be avoided by ensuring that patients:

  • are not sensitive to human normal immunoglobulin by initially injecting the product slowly (0.5 ml/kg BW/hr);
  • are carefully monitored for any symptoms throughout the infusion period. In particular, patients naive to human normal immunoglobulin, patients switched from an alternative IVIg product or when there has been a long interval since the previous infusion should be monitored at the hospital during the first infusion and for the first hour after the first infusion, in order to detect potential adverse signs. All other patients should be observed for at least 20 minutes after administration.
In all patients, IVIg administration requires:
      adequate hydration prior to the initiation of the infusion of IVIg
      monitoring of urine output
      monitoring of serum creatinine levels
      monitoring for signs and symptoms of thrombosis
      assessment of blood viscosity in patients at risk for hyperviscosity
      avoidance of concomitant use of loop diuretics (see 4.5).

In case of adverse reaction, either the rate of administration must be reduced or the infusion stopped. The treatment required depends on the nature and severity of the adverse reaction.

If dilution of KIOVIG to lower concentrations is required for patients suffering from diabetes mellitus, the use of 5% glucose solution for dilution may have to be reconsidered.

Hypersensitivity

Hypersensitivity reactions are rare.

Anaphylaxis can develop in patients  with undetectable IgA who have anti-IgA antibodies  who had tolerated previous treatment with human normal immunoglobulin

In case of shock, standard medical treatment for shock should be implemented.

Thromboembolism

There is clinical evidence of an association between IVIg administration and thromboembolic events such as myocardial infarction, cerebral vascular accident (including stroke), pulmonary embolism and deep vein thromboses which is assumed to be related to a relative increase in blood viscosity through the high influx of immunoglobulin in at-risk patients. Caution should be exercised in prescribing and infusion of IVIg in obese patients and in patients with pre-existing risk factors for thrombotic events (such as a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, hypertension, use of estrogens, diabetes mellitus and a history of vascular disease or thrombotic episodes, patients with acquired or inherited thrombophilic disorders, hypercoagulable disorders, patients with prolonged periods of immobilisation, severely hypovolaemic patients, patients with diseases which increase blood viscosity, patients with indwelling vascular catheters and patients with high dose and rapid infusion).

Hyperproteinemia, increased serum viscosity and subsequent relative pseudohyponatremia may occur in patients receiving IVIg therapy. This should be taken into account by physicians, since initiation of treatment for true hyponatremia (i.e. decreasing serum free water) in these patients may lead to a further increase in serum viscosity and a possible predisposition to thromboembolic events.

In patients at risk for thromboembolic adverse reactions, IVIg products should be administered at the minimum rate of infusion and dose practicable.

Acute renal failure

Cases of acute renal failure have been reported in patients receiving IVIg therapy. These include acute renal failure, acute tubular necrosis, proximal tubular nephropathy and osmotic nephrosis. In most cases, risk factors have been identified, such as pre-existing renal insufficiency, diabetes mellitus, hypovolaemia, overweight, concomitant nephrotoxic medicinal products, age over 65, sepsis, hyperviscosity or paraproteinemia.

Renal parameters should be assessed prior to infusion of IVIg, particularly in patients judged to have a potential increased risk for developing acute renal failure, and again at appropriate intervals. In patients at risk for acute renal failure, IVIg products should be administered at the minimum rate of infusion and dose practicable. In case of renal impairment, IVIg discontinuation should be considered.

While these reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IVIg products containing various excipients such as sucrose, glucose and maltose, those containing sucrose as a stabiliser accounted for a disproportionate share of the total number. In patients at risk, the use of IVIg products that do not contain these excipients may be considered. KIOVIG does not contain sucrose, maltose or glucose.

Transfusion Related Acute Lung Injury (TRALI)

In patients receiving IVIg, there have been reports of acute non-cardiogenic pulmonary edema (Transfusion Related Acute Lung Injury, (TRALI) in patients administered IVIg (including KIOVIG). TRALI is characterised by severe hypoxia, dyspnoea, tachypnoea, cyanosis, fever and hypotension. Symptoms of TRALI typically develop during or within 6 hours of a transfusion, often within 1-2 hours. Therefore, IVIg recipients must be monitored for and IVIg infusion must be immediately stopped in case of pulmonary adverse reactions. TRALI is a potentially lifethreatening condition requiring immediate intensive-care-unit management.

Aseptic meningitis syndrome (AMS)

Aseptic meningitis syndrome has been reported to occur in association with IVIg treatment. The syndrome usually begins within several hours to 2 days following IVIg treatment. Cerebrospinal fluid studies are frequently positive with pleocytosis up to several thousand cells per mm3, predominantly

from the granulocytic series, and elevated protein levels up to several hundred mg/dL. AMS may occur more frequently in association with high-dose (2 g/kg) IVIg treatment.

Patients exhibiting such signs and symptoms should receive a thorough neurological examination, including CSF studies, to rule out other causes of meningitis.

Discontinuation of IVIg treatment has resulted in remission of AMS within several days without sequelae.

From post-marketing data with KIOVIG no clear correlation of AMS to higher doses was observed. Higher incidences of AMS were seen in women.

Haemolytic anaemia

IVIg products can contain blood group antibodies that may act as haemolysins and induce in vivo coating of red blood cells with immunoglobulin, causing a positive direct antiglobulin reaction (Coombs' test) and, rarely, haemolysis. Haemolytic anaemia can develop subsequent to IVIg therapy due to enhanced red blood cells (RBC) sequestration. IVIg recipients should be monitored for clinical signs and symptoms of haemolysis. (See section 4.8.)

Neutropenia/Leukopenia

A transient decrease in neutrophil count and/or episodes of neutropenia, sometimes severe, have been reported after treatment with IVIgs. This typically occurs within hours or days after IVIg administration and resolves spontaneously within 7 to 14 days.

Interference with serological testing

After infusion of immunoglobulin the transitory rise of the various passively transferred antibodies in the patient's blood may result in misleading positive results in serological testing.

Passive transmission of antibodies to erythrocyte antigens, e.g. A, B, D, may interfere with some serological tests for red cell antibodies, for example the direct antiglobulin test (DAT, direct Coombs’ test).

Administration of KIOVIG can lead to false positive readings in assays that depend on detection of beta-D-glucans for diagnosis of fungal infections. This may persist during the weeks following infusion of the product.

Transmissible agents

KIOVIG is made from human plasma. Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infectious agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.

The measures taken are considered effective for enveloped viruses such as HIV, HBV and HCV, and for the non-enveloped viruses HAV and parvovirus B19.

There is reassuring clinical experience regarding the lack of hepatitis A or Parvovirus B19 transmission with immunoglobulins and it is also assumed that the antibody content makes an important contribution to the viral safety.

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Paediatric population

There are no paediatric specific risks with regard to any of the above adverse events. Paediatric patients may be more susceptible to volume overload (see Section 4.9).

Drug interactions

SmPC 4.5 Interactions with other medicinal products and other forms of interactions EU SmPC (EMA)

Live attenuated virus vaccines

Immunoglobulin administration may impair for a period of at least 6 weeks and up to 3 months the efficacy of live attenuated virus vaccines such as measles, rubella, mumps and varicella. After administration of this product, an interval of 3 months should elapse before vaccination with live attenuated virus vaccines. In the case of measles, this impairment may persist for up to 1 year. Therefore patients receiving measles vaccine should have their antibody status checked.

Dilution of KIOVIG with a 5% glucose solution may result in increased blood glucose levels.

Loop diuretics

Avoidance of concomitant use of loop diuretics.

Paediatric population

The listed interactions apply both to adults and children.

Adverse reactions

SmPC 4.8 Undesirable effects EU SmPC (EMA)

Summary of the safety profile

Adverse reactions such as chills, headache, dizziness, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally.

Rarely human normal immunoglobulins may cause a sudden fall in blood pressure and, in isolated cases, anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration.

Cases of reversible aseptic meningitis and rare cases of transient cutaneous reactions (including cutaneous lupus erythematosus - frequency unknown) have been observed with human normal immunoglobulin. Reversible haemolytic reactions have been observed in patients, especially those with blood groups A, B, and AB. Rarely, haemolytic anaemia requiring transfusion may develop after high dose IVIg treatment (see also Section 4.4).

Increase in serum creatinine level and/or acute renal failure have been observed.

Very rarely: Thromboembolic reactions such as myocardial infarction, stroke, pulmonary embolism, and deep vein thromboses.

Cases of Transfusion Related Acute Lung Injury (TRALI).

Tabulated list of adverse reactions

The tables presented below are according to the MedDRA system organ classification (SOC and Preferred Term Level). Table 1 shows the adverse reactions from clinical trials and Table 2 shows the post-marketing ARs.

Frequencies have been evaluated according to the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from available data).

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

                                                Table 1
             Frequency of Adverse Reactions (ADRs) in clinical studies with KIOVIG
        MedDRA
   System Organ Class                           Adverse reaction                          Frequency
          (SOC)
Infections and infestations Bronchitis, nasopharyngitis                                 Common
                            Chronic sinusitis, fungal infection, infection, kidney      Uncommon
                            infection, sinusitis, upper respiratory tract infection,
                            urinary tract infection, bacterial urinary tract infection,
                            meningitis aseptic
Blood and lymphatic         Anaemia, lymphadenopathy                                    Common
system disorders
Immune system disorders Hypersensitivity, anaphylactic reaction                         Uncommon
Endocrine disorders         Thyroid disorder                                            Uncommon
Metabolism and nutrition Decreased appetite                                             Common
disorders
Psychiatric disorders       Insomnia, anxiety                                           Common
                            Irritability                                                Uncommon
Nervous system disorders Headache                                                       Very common
                            Dizziness, migraine, paresthesia, hypoesthesia              Common

                                               Table 1
             Frequency of Adverse Reactions (ADRs) in clinical studies with KIOVIG
         MedDRA
   System Organ Class                          Adverse reaction                       Frequency
           (SOC)
                           Amnesia, dysarthria, dysgeusia, balance disorder,        Uncommon
                           tremor
Eye disorders              Conjunctivitis                                           Common
                           Eye pain, eye swelling                                   Uncommon
Ear and labyrinth          Vertigo, fluid in middle ear                             Uncommon
disorders
Cardiac disorders          Tachycardia                                              Common
Vascular disorders         Hypertension                                             Very common
                           Flushing                                                 Common
                           Peripheral coldness, phlebitis                           Uncommon
Respiratory, thoracic and  Cough, rhinorrhoea, asthma, nasal congestion,            Common
mediastinal disorders      oropharyngeal pain, dyspnea
                           Oropharyngeal swelling                                   Uncommon
Gastrointestinal disorders Nausea                                                   Very common
                           Diarrhoea, vomiting, abdominal pain, dyspepsia           Common
                           Abdominal distension                                     Uncommon
Skin and subcutaneous      Rash                                                     Very common
tissue disorders           Contusion, pruritus, urticaria, dermatitis, erythema     Common
                           Angioedema, acute urticaria, cold sweat,                 Uncommon
                           photosensitivity reaction, night sweats, hyperhidrosis
Musculoskeletal and        Back pain, arthralgia, pain in extremity, myalgia,       Common
connective tissue          muscle spasms, muscular weakness
disorders                  Muscle twitching                                         Uncommon
Renal and urinary          Proteinuria                                              Uncommon
disorders
General disorders and      Local reactions (e.g. infusion site                      Very common
administration site        pain/swelling/reaction/pruritus), pyrexia, fatigue
conditions                 Chills, edema, influenza-like illness, chest discomfort, Common
                           chest pain, asthenia, malaise, rigors
                           Chest tightness, feeling hot, burning sensation,         Uncommon
                           swelling
Investigations              Blood cholesterol increased, blood creatinine           Uncommon
                           increased, blood urea increased, white blood cell
                           count decreased, alanine aminotransferase increased,
                           haematocrit decreased, red blood cell count decreased,
                           respiratory rate increased

                                           Table 2
                            Post-Marketing Adverse Reactions (ARs)
        MedDRA
  System Organ Class                          Adverse reaction                        Frequency
         (SOC)
Blood and lymphatic         Haemolysis                                              Not known
system disorders
Immune system disorders     Anaphylactic shock                                      Not known
Nervous system disorders    Transient ischemic attack, cerebral vascular accident   Not known
Cardiac disorders           Myocardial infarction                                   Not known
Vascular disorders          Hypotension, deep vein thrombosis                       Not known
Respiratory, thoracic and   Pulmonary embolism, pulmonary edema                     Not known
mediastinal disorders

Table 2

Post-Marketing Adverse Reactions (ARs) MedDRA System Organ Class Adverse reaction Frequency (SOC) Investigations Coombs direct test positive, oxygen saturation Not known decreased Injury, poisoning and Transfusion-related acute lung injury Not known procedural complications

Description of selected adverse reactions

Muscle twitching and weakness were reported only in patients with MMN.

Paediatric population

Frequency, type and severity of adverse reactions in children are the same as in adults.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

For safety with respect to transmissible agents, see section 4.4.

Pregnancy considerations

SmPC 4.6 Fertility, pregnancy and lactation EU SmPC (EMA)

Pregnancy

The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore it should only be given with caution to pregnant women and breast-feeding mothers. IVIg products have been shown to cross the placenta, increasingly during the third trimester. Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus and the neonate are to be expected.

Breast-feeding

Immunoglobulins are excreted into the milk and may contribute to protecting the neonate from pathogens which have a mucosal portal of entry. No negative effects on the breastfed newborn/infants are anticipated.

Fertility

Clinical experience with immunoglobulins suggests that no harmful effects on fertility are to be expected.

Breastfeeding considerations

Breastfeeding is covered in SmPC 4.6 Fertility, pregnancy and lactation, under Pregnancy considerations above.

Overdose

SmPC 4.9 Overdose EU SmPC (EMA)

Overdose may lead to fluid overload and hyperviscosity, particularly in patients at risk, including elderly patients or patients with cardiac or renal impairment (see section 4.4 ).

Paediatric population

Smaller children below the age of 5 years may be particularly susceptible to volume overload. Therefore, dosing should be carefully calculated for this population. In addition, children with Kawasaki Disease are at especially high risk due to underlying cardiac compromise so dose and rate of administration should be carefully controlled.

Mechanism of action

SmPC 5.1 Pharmacodynamic properties EU SmPC (EMA)

Pharmacotherapeutic group: immune sera and immunoglobulins: immunoglobulins, normal human, for intravascular administration, ATC code: J06BA02

Human normal immunoglobulin contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against infectious agents.

Human normal immunoglobulin contains the IgG antibodies present in the normal population. It is usually prepared from pooled plasma from not fewer than 1000 donations. It has a distribution of immunoglobulin G subclasses closely proportional to that in native human plasma. Adequate doses of this medicinal product may restore abnormally low immunoglobulin G levels to the normal range.

The mechanism of action in indications other than replacement therapy is not fully elucidated, but includes immunomodulatory effects.

Paediatric population

There are no theoretical or observed differences in the action of immunoglobulins in children compared to adults.

Pharmacokinetics

SmPC 5.2 Pharmacokinetic properties EU SmPC (EMA)

Human normal immunoglobulin is immediately and completely bioavailable in the recipient’s circulation after intravenous administration. It is distributed relatively rapidly between plasma and extravascular fluid; after approximately 3 to 5 days equilibrium is reached between the intra- and extravascular compartments.

Pharmacokinetic parameters for KIOVIG were determined in the two clinical studies in PID patients performed in Europe and the US. In these studies, a total of 83 subjects at least 2 years of age were treated with doses of 300 to 600 mg/kg body weight every 21 to 28 days for 6 to 12 months. The median IgG half-life after administration of KIOVIG was 32.5 days. This half-life may vary from patient to patient, in particular in primary immunodeficiency. Pharmacokinetic parameters for the product are summarized in the table below. All parameters were analysed separately for three age groups, children (below 12 years, n=5), adolescents (13 to 17 years, n=10), and adults (above 18 years of age, n=64). The values obtained in the studies are comparable to parameters reported for other human immunoglobulins.

                        Summary of KIOVIG pharmacokinetic parameters
                                 Children             Adolescents               Adults
       Parameter           (12 years or below)      (13 to 17 years)      (18 years or above)
                          Median      95% CI*     Median      95% CI     Median      95% CI
Terminal half-life (days)   41.3     20.2 to 86.8  45.1     27.3 to 89.3   31.9    29.6 to 36.1
Cmin (mg/dl)/(mg/kg)
                            2.28     1.72 to 2.74  2.25     1.98 to 2.64   2.24    1.92 to 2.43
(trough level)
Cmax (mg/dl)/(mg/kg)
                            4.44     3.30 to 4.90  4.43     3.78 to 5.16   4.50    3.99 to 4.78
(peak level)
In-vivo recovery (%)        121       87 to 137     99       75 to 121     104       96 to 114
Incremental recovery
                            2.26     1.70 to 2.60  2.09     1.78 to 2.65   2.17    1.99 to 2.44
(mg/dl)/(mg/kg)
AUC0-21d (g·h/dl)
                            1.49     1.34 to 1.81  1.67     1.45 to 2.19   1.62    1.50 to 1.78
(area under the curve)
*CI – Confidence Interval

IgG and IgG-complexes are broken down in cells of the reticuloendothelial system.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Immunoglobulin, Normal, Human (IGIV) 50 mg/mL, 100 mL Vial₱9,500.00–₱11,778.00Reference ₱9,500.00per vialDPRI procurement range
Immunoglobulin, Normal, Human (IGIV) 50 mg/mL, 50 mL Vial₱4,260.00–₱6,667.00Reference ₱4,260.00per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Immunoglobulin Normal, Human (IGIM); Immunoglobulin Normal, Human (IGIV)
PNF listingInj.: 160 mg/mL, 2 mL, 5 mL and 10 mL vial (IM)
PNF listingInj.: 50 mg/mL, 10 mL, 20 mL, 50 mL, 100 mL and 200 mL vial (IV) freeze-dried powder, 1 g/bottle + 33 mL and 50 mL reconstitution fluid (IV) freeze-dried powder, 2.5 g/bottle + 100 mL reconstitution fluid (IV) freeze-dried powder, 5 g/bottle + 100 mL diluent vial (IV) freeze-dried powder, 10 g/bottle + 260 mL diluent vial (IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. European Medicines Agency. Kiovig: EPAR, product information, Annex I, Summary of Product Characteristics [EU SmPC, last updated June 27, 2022; no US FDA label]. https://www.ema.europa.eu/en/medicines/human/EPAR/kiovig © European Medicines Agency; reproduced with acknowledgment of the source.
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .